Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)

Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia

(2012) Matthew J. Olnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations

(2010) A. Pecci et al.   BLOOD

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study

(2010) Gregory Cheng et al.   LANCET

Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia

(2010) David J. Kuter et al.   NEW ENGLAND JOURNAL OF MEDICINE

International consensus report on the investigation and management of primary immune thrombocytopenia

(2009) D. Provan et al.   BLOOD

Eltrombopag

(2009) Karly P. Garnock-Jones et al.   DRUGS

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial

(2009) James B Bussel et al.   LANCET

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP

(2008) J. B. Bussel et al.   BLOOD

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

(2008) David J Kuter et al.   LANCET

Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist

(2008) Connie L. Erickson-Miller et al.   STEM CELLS